Morgan Stanley raised the firm’s price target on Roche (RHHBY) to CHF 290 from CHF 255 and keeps an Underweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche price target raised to CHF 300 from CHF 290 at Berenberg
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Roche receives FDA clearance with CLIA waiver for pertussis point-of-care test
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK